130 related articles for article (PubMed ID: 20878464)
1. Risk of second breast cancer according to estrogen receptor status and family history.
Bouchardy C; Benhamou S; Fioretta G; Verkooijen HM; Chappuis PO; Neyroud-Caspar I; Castiglione M; Vinh-Hung V; Vlastos G; Rapiti E
Breast Cancer Res Treat; 2011 May; 127(1):233-41. PubMed ID: 20878464
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of second cancer among patients with ovarian borderline tumors.
Bouchardy C; Fernandez S; Merglen A; Usel M; Fioretta G; Rapiti E; Schubert H; Pelte MF; Chappuis PO; Vlastos G
Gynecol Oncol; 2008 May; 109(2):210-4. PubMed ID: 18377966
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.
Sandberg ME; Hartman M; Klevebring D; Eloranta S; Ploner A; Hall P; Czene K
Breast Cancer Res Treat; 2012 Jul; 134(2):793-800. PubMed ID: 22622811
[TBL] [Abstract][Full Text] [Related]
5. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status.
Bardia A; Hartmann LC; Vachon CM; Vierkant RA; Wang AH; Olson JE; Sellers TA; Cerhan JR
Arch Intern Med; 2006 Dec 11-25; 166(22):2478-83. PubMed ID: 17159013
[TBL] [Abstract][Full Text] [Related]
6. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
[TBL] [Abstract][Full Text] [Related]
7. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
Brown M; Bauer K; Pare M
Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
9. Body weight correlates with mortality in early-stage breast cancer.
Enger SM; Greif JM; Polikoff J; Press M
Arch Surg; 2004 Sep; 139(9):954-58; discussion 958-60. PubMed ID: 15381612
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect between alcohol and estrogen replacement therapy on risk of breast cancer differs by estrogen/progesterone receptor status in the Iowa Women's Health Study.
Gapstur SM; Potter JD; Drinkard C; Folsom AR
Cancer Epidemiol Biomarkers Prev; 1995 Jun; 4(4):313-8. PubMed ID: 7655324
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk factors and second primary malignancies among women with breast cancer.
Trentham-Dietz A; Newcomb PA; Nichols HB; Hampton JM
Breast Cancer Res Treat; 2007 Oct; 105(2):195-207. PubMed ID: 17186360
[TBL] [Abstract][Full Text] [Related]
12. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.
Miyoshi Y; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2003 Jun; 9(6):2229-33. PubMed ID: 12796390
[TBL] [Abstract][Full Text] [Related]
13. Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972-2001.
Soerjomataram I; Louwman WJ; de Vries E; Lemmens VE; Klokman WJ; Coebergh JW
Breast Cancer Res Treat; 2005 Sep; 93(1):91-5. PubMed ID: 16184464
[TBL] [Abstract][Full Text] [Related]
14. Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study.
Cluze C; Delafosse P; Seigneurin A; Colonna M
Eur J Cancer Prev; 2009 Sep; 18(5):343-8. PubMed ID: 19436213
[TBL] [Abstract][Full Text] [Related]
15. A comparison of bilateral breast cancers in BRCA carriers.
Weitzel JN; Robson M; Pasini B; Manoukian S; Stoppa-Lyonnet D; Lynch HT; McLennan J; Foulkes WD; Wagner T; Tung N; Ghadirian P; Olopade O; Isaacs C; Kim-Sing C; Møller P; Neuhausen SL; Metcalfe K; Sun P; Narod SA
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1534-8. PubMed ID: 15941968
[TBL] [Abstract][Full Text] [Related]
16. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there?
Potter JD; Cerhan JR; Sellers TA; McGovern PG; Drinkard C; Kushi LR; Folsom AR
Cancer Epidemiol Biomarkers Prev; 1995 Jun; 4(4):319-26. PubMed ID: 7655325
[TBL] [Abstract][Full Text] [Related]
17. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
18. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women.
Nichols HB; Trentham-Dietz A; Love RR; Hampton JM; Hoang Anh PT; Allred DC; Mohsin SK; Newcomb PA
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):41-7. PubMed ID: 15668474
[TBL] [Abstract][Full Text] [Related]
19. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
20. Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women.
Zeleniuch-Jacquotte A; Toniolo P; Levitz M; Shore RE; Koenig KL; Banerjee S; Strax P; Pasternack BS
Cancer Epidemiol Biomarkers Prev; 1995 Dec; 4(8):857-60. PubMed ID: 8634657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
